Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats

Hypertension Research

Volumn 31, Issue 1, 2008, Pages 135-140

  Kamari, Yehuda ^a,b   Harari, Ayelet ^a,b   Shaish, Aviv ^a,b   Peleg, Edna ^a,b   Sharabi, Yehonatan ^a,b   Harats, Dror ^a,b   Grossman, Ehud ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adiponectin; Metabolic syndrome; Peroxisome proliferator activated receptor ; Telmisartan

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; FRUCTOSE; INSULIN; TELMISARTAN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MALE; NONHUMAN; RAT; RECEPTOR BLOCKING; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; DIET; FRUCTOSE; HYPERINSULINISM; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN; MALE; METABOLIC SYNDROME X; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 40149085377     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.135     Document Type: Article

References (35)

1. Velarde G, Berk BC: Role of hypertension in the metabolic syndrome: who is affected? Curr Hypertens Rep 2005; 7: 418-426.
2. Behn A, Ur E: The obesity epidemic and its cardiovascular consequences. Curr Opin Cardiol 2006; 21: 353-360.
3. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
5. Cooper ME, Tikellis C, Thomas MC: Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. J Hypertens Suppl 2006; 24: S57-S63.
6. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME: Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-473.
7. Scheen AJ: Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004; 30: 498-505.
8. Derosa G, Cicero AF, D'Angelo A, et al: Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-α. Hypertens Res 2006; 29: 849-856.
9. Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K: Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 2003; 26: 705-710.
10. Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007; 18: 263-270.
11. Rabin KR, Kamari Y, Avni I, Grossman E, Sharabi Y: Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 2005; 3: 465-471.
12. Yamauchi T, Kamon J, Waki H, et al: Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468.
13. Combs TP, Pajvani UB, Berg AH, et al: A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145: 367-383.
14. Sharma AM, Staels B: Review: peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386-395.
15. Sharabi Y, Oron-Herman M, Kamari Y, et al: Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am J Hypertens 2007; 20: 206-210.
16. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
17. Schupp M, Janke J, Clasen R, Unger T, Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
18. Clasen R, Schupp M, Foryst-Ludwig A, et al: PPAR-gamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143.
19. Benndorf RA, Rudolph T, Appel D, et al: Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55:, 1159-1164.
20. Erbe DV, Gartrell K, Zhang YL, et al: Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006; 45: 154-162.
21. Kamari Y, Grossman E, Oron-Herman M, et al: Metabolic stress with a high carbohydrate diet increases adiponectin levels. Horm Metab Res 2007; 39: 384-388.
22. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW: Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003-1009.
23. Kintscher U, Law RE: PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 2005; 288: E287-E291.
24. Yang B, Brown KK, Chen L, et al: Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004; 4: 23.
25. Iwaki M, Matsuda M, Maeda N, et al: Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663.
26. Boden G, Zhang M: Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006; 15: 243-250.
27. Yamaguchi K, Ura N, Murakami H, et al: Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle. Hypertens Res 2005; 28: 773-778.
28. Okada K, Hirano T, Ran J, Adachi M: Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructosefed rats. Hypertens Res 2004; 27: 293-299.
29. Shimamoto K, Matsuda K, Takizawa H, Higashiura K, Ura N, Iimura O: Effects of an angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructose-fed rats. Blood Press Suppl 1994; 5: 113-116.
30. Oron-Herman M, Sela BA, Rosenthal T: Risk reduction therapy for syndrome X: comparison of several treatments. Am J Hypertens 2005; 18: 372-378.
31. Kouyama R, Suganami T, Nishida J, et al: Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005; 146: 3481-3489.
32. Mori Y, Itoh Y, Tajima N: Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2007; 20: 431-436.
33. Janke J, Schupp M, Engeli S, et al: Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 2006; 24: 1809-1816.
34. Furuhashi M, Ura N, Takizawa H, et al: Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-1982.
35. Roglans N, Vila L, Farre M, et al: Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology 2007; 45: 778-788.